Phase II study of adjuvant gemcitabine plus docetaxel (GD) for completely resected stage I-IV high grade uterine leiomyosarcoma (HGuLMS)

被引：0
|
作者：
Hensley, M. L. [1 ]
Larkin, J. [1 ]
Ishill, N. [1 ]
Abu-Rustum, N. [1 ]
Sabbatini, P. [1 ]
Konner, J. [1 ]
Tew, W. [1 ]
Spriggs, D. [1 ]
Aghajanian, C. A. [1 ]
机构：
[1] Memor Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5591
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer
    Matsui, K
    Hirashima, T
    Nitta, T
    Kobayashi, M
    Ogata, Y
    Furukawa, M
    Kudoh, S
    Yoshimura, N
    Mukohara, T
    Yamauchi, S
    Shiraishi, S
    Kamoi, H
    Negoro, S
    Takeda, K
    Nakagawa, K
    Takada, M
    Yana, T
    Fukuoka, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 181 - 187
  • [42] TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
    Soo, R.
    De Marinis, F.
    Han, J. -Y.
    Ho, C. M. J.
    Lin, Y.
    Servidio, L.
    Sandelin, M.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S272 - S272
  • [43] Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
    Hensley, Martee L.
    Miller, Austin
    O'Malley, David M.
    Mannel, Robert S.
    Behbakht, Kian
    Bakkum-Gamez, Jamie N.
    Michael, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1180 - 1185
  • [44] A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer
    Tomizawa, Yoshio
    Ishihara, Shin-ichi
    Iijima, Hironobu
    Imai, Hisao
    Sato, Koji
    Yatomi, Masakiyo
    Iwasaki, Yasuki
    Yamada, Hidenori
    Kobayashi, Go
    Ishida, Emi
    Inoue, Teruki
    Aoki, Haruka
    Watanabe, Satoru
    Kawashima, Osamu
    Mori, Masatomo
    Saito, Ryusei
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (05): : 498 - 502
  • [45] PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH TRI-WEEKLY CARBOPLATIN PLUS DOCETAXEL IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER: INTERIM ANALYSIS
    Uramoto, Hidetaka
    Nakanishi, Ryoichi
    Sugaya, Masakazu
    Uchiyama, Akihiko
    Inoue, Masaaki
    Iwata, Teruo
    Ebi, Noriyuki
    Hanagiri, Takeshi
    Tanaka, Fumihiro
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S475 - S475
  • [46] Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study
    Sutton, G
    Kauderer, J
    Carson, LF
    Lentz, SS
    Whitney, CW
    Gallion, H
    GYNECOLOGIC ONCOLOGY, 2005, 96 (03) : 630 - 634
  • [47] A Randomized Phase II Trial of Adjuvant Chemotherapy with Bi-weekly Carboplatin plus Paclitaxel versus Carboplatin plus Gemcitabine in Patients with Completely Resected Non-small Cell Lung Cancer
    Uramoto, Hidetaka
    Nakanishi, Ryoichi
    Nagashima, Akira
    Uchiyama, Akihiko
    Inoue, Masaaki
    Osaki, Toshihiro
    Yoshimatsu, Takashi
    Sakata, Hisanobu
    Nakanishi, Kozo
    Yasumoto, Kosei
    ANTICANCER RESEARCH, 2010, 30 (11) : 4695 - 4699
  • [48] Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
    Khushalani, Nikhil, I
    Vassallo, Melinda
    Goldberg, Judith D.
    Eroglu, Zeynep
    Kim, Younchul
    Cao, Biwei
    Ferguson, Robert
    Monson, Kelsey R.
    Kirchhoff, Tomas
    Amato, Carol M.
    Burke, Paulo
    Strange, Ann
    Monk, Emily
    Gibney, Geoffrey Thomas
    Kudchadkar, Ragini
    Markowitz, Joseph
    Brohl, Andrew S.
    Pavlick, Anna
    Richards, Alison
    Woods, David M.
    Weber, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)
  • [49] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
    L. G. Estévez
    P. Sánchez-Rovira
    M. Dómine
    A. León
    I. Calvo
    A. Jaén
    V. Casado
    G. Rubio
    M. Díaz
    C. Miró
    F. Lobo
    E. Carrasco
    M. Casillas
    B. San Antonio
    Clinical and Translational Oncology, 2007, 9 : 317 - 322
  • [50] Multicentre randomized phase II study with Gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC
    Ricci, S
    Antonuzzo, A
    Galli, L
    Algeri, R
    Bonifazi, V
    Andrei, A
    Petruzzelli, S
    Dupre, C
    Pegna, AL
    Conte, PF
    ANNALS OF ONCOLOGY, 1998, 9 : 95 - 95
12345